Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Emerging Companies

Doctors move dementia assessment from paper to smartphone

Evidence-based ACEmobile app soon to be launched

EISAI

Eisai “appalled” at decision not to recommend Fycompa in Germany

Regulator says pharma company filed inadequate comparison data for its epilepsy drug

- PMLiVE

Bayer fails to overturn Nexavar compulsory licence in India

Natco Pharma allowed to sell cut-price version of cancer drug

- PMLiVE

Roche gains EU approval for Perjeta in breast cancer

Available in combination with Herceptin and docetaxel chemotherapy

Roche - Basel

Roche’s Herceptin follow-up cleared in US

FDA approval for Kadcyla (formerly T-DM1) in breast cancer

- PMLiVE

Late-stage failure for Merck’s cilengitide in brain cancer

Integrin inhibitor unable to improve overall survival in phase III trials

- PMLiVE

Janssen teams up with the NHS for dementia challenge

£150,000 innovation prize aims to identify and reward novel approaches to care

- PMLiVE

FDA fast-tracks Bayer’s prostate cancer radiotherapy

Priority review for radium-223 dichloride, formerly called Alpharadin

- PMLiVE

David Cameron wants UK to become more ‘dementia friendly’

Prime minister takes part in first DH sponsored Dementia Friends session

e-Therapeutics raises £40m to support oncology pipeline

Will fund development of ETS2101 for brain cancer and other potential indications

Just Health PR wins Caris Life Sciences brief

Bioscience company to launches its tumour profiling technology in Europe

- PMLiVE

Celgene gets US green light for blockbuster candidate Pomalyst

FDA approval to treat multiple myeloma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links